Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.

Studied

Randomized comparison of semaglutide with placebo, tracking kidney failure, major kidney-function loss, or kidney-related or cardiovascular death.

Who / model

3533 participants with type 2 diabetes and chronic kidney disease; median follow-up was 3.4 years.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

The primary outcome risk was 24% lower with semaglutide, with 331 versus 410 first events. Confirmatory secondary outcomes showed slower kidney-function decline, 18% lower cardiovascular-event risk and 20% lower death risk. Serious adverse events occurred in 49.6% versus 53.8%.

Limits

The abstract reports an early-stop recommendation following a planned interim analysis.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary